Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

33
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
33
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

73
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
73
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

515
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
515
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.2K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.5K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Multifactorial analysis of the pyuria after transurethral prostatectomy].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology·1992
Same author

[Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].

Hinyokika kiyo. Acta urologica Japonica·1992
Same author

The activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice immunized with type II collagen.

Biochemical medicine and metabolic biology·1992
Same author

Solid-phase anti-CD3 antibody activation and cryopreservation of human tumor-infiltrating lymphocytes derived from epithelial ovarian cancer.

Japanese journal of cancer research : Gann·1992
Same author

Mouse dopamine beta-hydroxylase: primary structure deduced from the cDNA sequence and exon/intron organization of the gene.

Biochemical and biophysical research communications·1992
Same author

Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase.

Biochemistry·1992

Related Experiment Video

Updated: Feb 24, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Preclinical approach for identifying drug interactions

T Kamataki1, T Yokoi, K Fujita

  • 1Division of Pharmacobio-dynamics, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Cancer Chemotherapy and Pharmacology
|September 28, 1998
PubMed
Summary

Drug interactions involving Cytochrome P450 (CYP) enzymes can alter anticancer drug levels. Dexamethasone decreased docetaxel levels, while ketoconazole may increase them, impacting treatment efficacy.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.6K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.8K

Related Experiment Videos

Last Updated: Feb 24, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.6K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.8K

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Oncology

Background:

  • Drug interactions significantly impact therapeutic outcomes, particularly with anticancer agents metabolized by Cytochrome P450 (CYP) enzymes.
  • CYP enzymes, especially CYP3A4, play a crucial role in metabolizing various drugs, including docetaxel.
  • Understanding enzyme induction and inhibition is vital for managing drug efficacy and toxicity.

Purpose of the Study:

  • To investigate the impact of CYP3A4 inducers and inhibitors on the pharmacokinetics of docetaxel.
  • To explore the potential of novel anticancer agents, like JM216, to inhibit major CYP isoforms.

Main Methods:

  • Administering dexamethasone (CYP3A inducer) to mice and measuring serum docetaxel concentrations.
  • Assessing the inhibitory potential of JM216 on major CYP isoforms in human liver microsomes.

Main Results:

  • Dexamethasone administration led to decreased serum docetaxel concentrations in mice.
  • Ketoconazole is hypothesized to increase docetaxel serum and hepatic concentrations.
  • JM216 demonstrated significant inhibition of major CYP450 enzymes in human liver microsomes.

Conclusions:

  • CYP3A4 inducers and inhibitors can alter docetaxel pharmacokinetics, necessitating careful co-administration.
  • JM216 exhibits broad CYP450 inhibition, requiring thorough evaluation for drug-drug interactions in clinical settings.